vimarsana.com

Latest Breaking News On - Aimmune therapeutics - Page 8 : vimarsana.com

Immune Therapeutics (OTCMKTS:IMUN) Stock Price Down 3 2%

Shares of Immune Therapeutics, Inc. (OTCMKTS:IMUN – Get Free Report) fell 3.2% during mid-day trading on Monday . The company traded as low as $0.26 and last traded at $0.29. 363 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 15,492 shares. The stock had previously closed at […]

Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH

Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Environmental Factors and Advancements in Immunotherapies Propel Growth of Global Allergy Treatment Market to 2027

Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

Head to Head Analysis: Regeneron Pharmaceuticals (NASDAQ:REGN) and Immune Therapeutics (OTCMKTS:IMUN)

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) and Immune Therapeutics (OTCMKTS:IMUN – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations. Profitability This table compares Regeneron Pharmaceuticals and Immune […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.